HOME › Press Releases › Mycoplasma Testing Market worth $613.49 Million by 2019
Mycoplasma Testing Market worth $613.49 Million by 2019
The report “Mycoplasma Testing Market by Products (Instruments, Kits & Reagents, Services), Application (Cell Line, Virus, End of Production Cells), Technology (PCR, ELISA, Direct Assay), End User (Cell Banks, Pharmaceutical Companies) - Global Forecast to 2019”, is expected to reach $613.49 Million by 2019 from $340.29 Million in 2014, growing at a CAGR of 12.51% between 2014 and 2019.
Browse 74 market data tables and 103 figures spread through 175 pages and in-depth TOC on “Mycoplasma Testing Market by Products (Instruments, Kits & Reagents, Services), Application (Cell Line, Virus, End of Production Cells), Technology (PCR, ELISA, Direct Assay), End User (Cell Banks, Pharmaceutical Companies) - Global Forecast to 2019"
Early buyers will receive 10% customization on reports.
The report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global mycoplasma testing market along with the estimates and forecasts of the revenue and market share analysis.
The global market is poised for rapid growth between 2014 and 2019. The growth in pharmaceutical industry and government funding for drug discovery and life sciences are important reasons for the growth in market size.
Increasing number of biotechnology & pharmaceutical companies will also aid the growth of the mycoplasma testing market. Today, The global biopharmaceutical revenues in 2014 are estimate to be $163 Billion, contributing to about 20% of the pharmaceutical market. It is the fastest growing area of the industry. According to estimates from the IMS Institute of Healthcare Informatics, the global pharmaceutical industry is expected to grow at a CAGR between 7% and 12% in the forecast period (2014 to 2019). The Asia-Pacific region is expected to witness the highest CAGR in this industry; growth rates are expected to be as high as 11% to 14% in emerging markets. This high growth rate, along with the substantial size of R&D spending on drug discovery projects, will act as an important driver of the mycoplasma testing market. Increased research and development spending by pharmaceutical and biotechnology companies aided by increasing drug development research, which has a strong upward trend worldwide and is expected to drive the mycoplasma testing market.
The market is segmented on the basis of by products, technology, applications, and end users. Of these, the global mycoplasma testing market products segment comprises of instruments, kits & reagents and services markets. Kits & reagents had the largest share of the mycoplasma testing market in 2014 and are expected to grow at the highest CAGR between 2014 and 2019. The kits & reagent segment is further divided on the basis of type into stains, elimination kits, PCR assays, nucleic acid detection kits, standards & controls and other kits & reagents.
The technology segment includes microbial culture techniques, DNA staining, PCR, ELISA, direct assay, indirect assay and enzymatic methods. The applications included in this report are cell line testing, virus testing, end of production cells testing and other applications. The cell line testing applications had the largest share of the mycoplasma testing market in 2014. The cell line testing applications are expected to one of the fastest growing applications between 2014 and 2019.
The geographic segments included in this report are North Americas, Europe, Asia and Rest of the World (RoW). North America has the largest share of this market in 2014, while Asia is expected to grow at the fastest rate during the forecast period. Growth in the Asian mycoplasma testing market will primarily be driven by the rapid increase in R&D expenditure in this region.
The major players in the mycoplasma testing market include Merck KGaA (Germany), Sigma-Aldrich (U.S.), Thermo Fisher Scientific (U.S.), Lonza Group Ltd. (Switzerland), Charles River Laboratories International, Inc. (U.S.), Promo Cell GmbH (Germany), Bionique Testing Laboratories, Inc.(France), American Type Culture Collection (U.S.), InvivoGen.(U.S.), Biological Industries Israel Beit Haemek Ltd. (Israel) and others.
MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252